Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07463846 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate ALN-2232 in Participants With Obesity

StatusRecruiting
PhasePhase 1/2
Started2026-03-02
View on ClinicalTrials.gov ↗

Amendment history

2026-08-11
3 amendments v2-v4
3 re-verifications since 2026-06-10, no change to tracked fields
2026-05-12
Study Status, Contacts/Locations v1
Primary completion moved earlier: 2028-02-01 → 2027-04-27
Completion date2028-03-01→2028-03-02
Study sitesdetails revised at 1 of 1 site
2026-03-06
Original filing
Alnylam Pharmaceuticals
31 trials monitored
See 5 trials at risk
Obesity
3,523 trials monitored
See 133 trials at risk
The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
Trial Details
NCT Number NCT07463846
Lead Sponsor Alnylam Pharmaceuticals
Conditions Obesity
Enrollment 156 participants
Start Date 2026-03-02
Primary Completion 2027-04-27 (estimated)
Study Completion 2028-03-02 (estimated)
Updated on ClinicalTrials.gov 2026-09-16